Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linzagolix long-term extension in endometriosis-associated pain
2019-002410-39Phase 3Completed
- Sponsor
- ObsEva SA
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of linzagolix in endometriosis (2 arms), sponsored by ObsEva SA. Primary endpoints: Clinically meaningful reduction in dysmenorrhea at Month 12 and Clinically meaningful reduction in non-menstrual pelvic pain at Month 12. Started Jan 2020; status: completed.
02
Drugs
linzagolix
03
Conditions
endometriosis
Beyond the preview
Go deeper on 2019-002410-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002410-39.